| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 15, 2026 | HHS Launches $4M EMPOWER Prize Challenge to Enhance Living Kidney Donation | What You Should Know
The Challenge: The U.S. Department of Health and Human Services (HHS) has launched the 2026 KidneyX EMPOWER Prize Challenge, a $4M national competition to accelerate innovations supporting living kidney donors.
The Core... |
| Nov 11, 2025 | Vexev's VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics | VxWave Ultrasound Imaging System demonstrated 94% scanning success rate and 100% data adequacy rate for vascular access creation strategies in CANSCAN trial
New insights into vascular anatomy made possible by standardized image acquisition ... |
| Feb 25, 2025 | MediBeacon® Transdermal GFR System receives device approval in China; Peer-reviewed articles on MediBeacon technology published | Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.
The Clinical Kidney Journal in February published MediBeacon study results on measu... |
| Dec 12, 2024 | KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 ...... | SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat h... |
| Oct 16, 2024 | Bridging the Gap: Innovations in Kidney Care and Clinical Trial Diversity | In the realm of healthcare, innovation and inclusivity are two powerful forces. They shape the future of treatment and ensure that advancements benefit everyone. Recent developments in kidney care and clinical trial participation highlight ... |
| Oct 16, 2024 | The Future of Healthcare: MDisrupt and Vivance Lead the Charge | In the ever-evolving landscape of healthcare, innovation is the lifeblood that fuels progress. Two companies, MDisrupt and Vivance, are at the forefront of this revolution, each tackling unique challenges in the health tech arena. Their rec... |
| Oct 14, 2024 | Vivance Completes Pre-Pivotal Trial of Wearable Dialysis Device; Results to be Shared at ASN Kidney Week 2024 | SINGAPORE, Oct. 14, 2024 /PRNewswire/ -- Vivance, a leader in kidney care innovations, is proud to announce that the next trial phase of the wearable peritoneal dialysis (PD) device, Viva Kompact, has successfully concluded. The study was c... |
| Sep 12, 2024 | HHS launches $7.25 million KidneyX Sustainability Prize | Challenge seeks solutions that reduce water or power used during dialysis
Today, the U.S. Department of Health and Human Services (HHS) launched the KidneyX Sustainability Prize, a $7.25 million challenge to drive meaningful change in the s... |
| Jul 18, 2024 | Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration | SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| Jun 6, 2024 | Telehealth System Featuring Rokid Glass 2 Wins HHS Award | HANGZHOU, China, June 6, 2024 /PRNewswire/ -- Rokid's augmented reality (AR) devices are making significant inroads into the medical sector. Utilizing the industrial-grade, split monocular waveguide AR glasses Rokid Glass 2, Rokid's Partner... |
| May 14, 2024 | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Tue, May 14, 2024 13:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its pa... |
| Oct 19, 2023 | Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 | Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Thu, Oct 19, 2023 08:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”... |
| Sep 14, 2023 | Awak raises $20m series B for on-the-go kidney dialysis machines | InvestmentsNews
Miguel Cordon · 14 Sep 2023 · 2 min readAwak raises $20m series B for on-the-go kidney dialysis machines
The Awak Singapore team / Photo credit: Awak
Kidney diseases have been called a “hidden epidemic” by some, with the chr... |
| Feb 2, 2023 | There Should Be An Urgency To Increase The Number Of Kidneys Available For Transplant | The United States has a government agency solely devoted to reducing automobile deaths in the United States, and it spends billions of dollars each year—and requires auto companies to do likewise—in an attempt to make our nation’s roads and... |
| Nov 9, 2022 | ASN: Discontinuation of RAS Inhibitors Does Not Increase eGFR in CKD | WEDNESDAY, Nov. 9, 2022 (HealthDay News) -- For patients with advanced and progressive chronic kidney disease, discontinuation of treatment with renin-angiotensin system (RAS) inhibitors is not associated with a difference in the long-term ... |
| Aug 11, 2022 | KidneyX Launches New Artificial Kidney Prize with $10.5 Million in Funding | Today, the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) announced a new prize competition from the Kidney Innovation Accelerator (KidneyX) that seeks to further the development of a fully f... |
| Nov 16, 2021 | FAQ: Why is the cystatin C test perceived to be costly? | In this segment we are answering questions our Product Manager for cystatin C and our Product Specialist in the US receive about cystatin C and our cystatin C immunoassay at exhibitions, conferences, and client meetings. Today's question is... |
| Nov 5, 2021 | GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease | For media and investors only
Issued: 5 November, London UK
Late-breaking data from the daprodustat ASCEND-ND and ASCEND-D trials at the American Society of Nephrology's Kidney Week 2021 confirms the potential for a new oral treatment for pa... |
| Nov 5, 2021 | PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline | Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes
PromarkerD correctly identified 84% of patients with normal ki... |
| Nov 3, 2021 | Calliditas announces poster presentations at ASN Digital Kidney Week 2021 | Calliditas announces poster presentations at ASN Digital Kidney Week 2021 Wed, Nov 03, 2021 08:00 CET
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced upcoming presentations concerning Nefeco... |
| Nov 3, 2021 | Calliditas announces poster presentations at ASN Digital Kidney Week 2021 | Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) annual Kidney Wee... |
| Oct 19, 2021 | Akebia Therapeutics : Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021 | CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Soc... |
| Apr 13, 2021 | American Society of Nephrology Renews Journal Hosting on HighWire’s JCore Platform | “It was clear that HighWire was the right choice to ensure that we remain on a highly flexible and efficient platform, while sitting at the cutting edge of innovation, search engine optimization and third-party integration.”
PRINCETON, N.J.... |
| Feb 4, 2021 | Gentian Diagnostics : A brief history on the estimation of Glomerular Filtration Rate | Glomerular filtration rate (GFR) is a measure of how much blood is filtered by the kidneys each minute. It is the best overall indicator for how well an individual's kidneys are functioning at a given moment.
Estimating GFR with cystatin C ... |
| Sep 25, 2020 | Palladio bags $20 million Series B to topple a problematic kidney disease drug | Palladio Biosciences just took one step further in its quest to topple Otsuka’s Samsca with its own — it hopes safer — autosomal dominant polycystic kidney disease (ADPKD) drug.
Alex Martin
The Pennsylvania-based biote... |
| Nov 20, 2019 | HHS Launches $1.5M Second Phase of KidneyX Prize Competition to Redesign Dialysis | – KidneyX launches the $1.5 million second phase of the Redesign Dialysis prize competition.
– Redesign Dialysis Phase 2 seeks prototype solutions or components of solutions, that can replicate normal kidney functions or improve dialysis ac... |
| Jul 24, 2019 | A simple bureaucratic organ donation fix will save thousands of lives | The partisan debates raging across the U.S. are often framed as a battle for the nation’s soul. The battle for our nation’s organs, however, is a distinctly more bipartisan affair.
Both President Trump — via executive order — and elected of... |
| Why there is great need for additional treatments to manage hyperphosphatemia in patients with CKD on dialysis | About 15% of adults in the United States (US) have chronic kidney disease (CKD), and 1 in 3 US adults are at risk for CKD. Nearly 560,000 US adults are on dialysis. Minorities are disproportionately affected by CKD and end-stage renal disea... |